Weight-loss drugs beyond weight-loss: The potential of GLP-1 to mitigate cardiovascular disease and other conditions
Weight-loss drugs such as Wegovy are on the rise, driving up the value of the companies, such as Novo Nordisk, that sell them.While they are predominantly aimed at treating diabetes and obesity, a new perspective, published in the journal Science, suggests that they have a range of other potential benefits. How could this impact the food